KIR3DL2
Template:Short description Template:Cs1 config An Error has occurred retrieving Wikidata item for infobox Killer cell immunoglobulin-like receptor 3DL2 is a protein that in humans is encoded by the KIR3DL2 gene.[1][2][3]
Structure
Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed on natural killer (NK) cells and subsets of T cells. KIR proteins are classified based on the number of extracellular immunoglobulin (Ig) domains—either two (2D) or three (3D)—and the length of their cytoplasmic tails: long (L) or short (S).
KIR3DL2 is a member of the 3DL family, containing three Ig-like domains and a long cytoplasmic tail. The long tail includes one or more immune tyrosine-based inhibitory motifs (ITIMs), which mediate inhibitory signaling upon ligand engagement. In contrast, KIRs with short cytoplasmic tails lack ITIMs and instead signal through association with TYRO protein tyrosine kinase binding protein, resulting in activating signals.
The KIR genes are polymorphic and highly homologous, clustered on chromosome 19q13.4 within the 1 Mb leukocyte receptor complex (LRC). The gene content of this cluster varies among haplotypes, but several "framework" genes—including KIR3DL2—are found in all haplotypes.[3]
Function
KIR3DL2 is involved in the regulation of innate immune responses, primarily through its expression on NK cells and γδ T cells, a subset of non-MHC-I-restricted T cells.[4]
The ligand for KIR3DL2 includes subsets of HLA class I molecules, and interaction with these ligands typically transduces inhibitory signals that suppress NK cell-mediated cytotoxicity. In addition, the protein IGSF8 (Immunoglobulin superfamily member 8) has been identified as a binding partner of KIR3DL2.[4] Engagement of KIR3DL2 by IGSF8 functions as an immune checkpoint that inhibits NK cell cytotoxic activity, highlighting its role in immune evasion mechanisms in cancer.[4]
See also
References
Page Template:Reflist/styles.css has no content.
- ^ Page Module:Citation/CS1/styles.css has no content.Colonna M, Samaridis J (April 1995). "Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells". Science. 268 (5209): 405–408. Bibcode:1995Sci...268..405C. doi:10.1126/science.7716543. PMID 7716543.
- ^ Page Module:Citation/CS1/styles.css has no content.Döhring C, Samaridis J, Colonna M (Aug 1996). "Alternatively spliced forms of human killer inhibitory receptors". Immunogenetics. 44 (3): 227–230. doi:10.1007/BF02602590. PMID 8662091. S2CID 38478576.
- ^ a b Page Module:Citation/CS1/styles.css has no content."Entrez Gene: KIR3DL2 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2".
- ^ a b c Page Module:Citation/CS1/styles.css has no content.Li Y, Wu X, Sheng C, Liu H, Liu H, Tang Y, et al. (May 2024). "IGSF8 is an innate immune checkpoint and cancer immunotherapy target". Cell. 187 (11): 2703–2716.e23. doi:10.1016/j.cell.2024.03.039. PMID 38657602.
Further reading
Page Template:Refbegin/styles.css has no content.
- Page Module:Citation/CS1/styles.css has no content.Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, et al. (May 1995). "Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains". Immunity. 2 (5): 439–449. doi:10.1016/1074-7613(95)90025-X. PMID 7749980.
- Page Module:Citation/CS1/styles.css has no content.Döhring C, Scheidegger D, Samaridis J, Cella M, Colonna M (May 1996). "A human killer inhibitory receptor specific for HLA-A1,2". Journal of Immunology. 156 (9): 3098–3101. doi:10.4049/jimmunol.156.9.3098. PMID 8617928.
- Page Module:Citation/CS1/styles.css has no content.Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, di Donato C, et al. (August 1996). "The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer". The Journal of Experimental Medicine. 184 (2): 505–518. doi:10.1084/jem.184.2.505. PMC 2192700. PMID 8760804.
- Page Module:Citation/CS1/styles.css has no content.Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO (December 1995). "Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer". Immunity. 3 (6): 801–809. doi:10.1016/1074-7613(95)90069-1. PMID 8777725.
- Page Module:Citation/CS1/styles.css has no content.Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, et al. (December 1997). "Human diversity in killer cell inhibitory receptor genes". Immunity. 7 (6): 753–763. doi:10.1016/S1074-7613(00)80394-5. PMID 9430221.
- Page Module:Citation/CS1/styles.css has no content.Kwon D, Chwae YJ, Choi IH, Park JH, Kim SJ, Kim J (February 2000). "Diversity of the p70 killer cell inhibitory receptor (KIR3DL) family members in a single individual". Molecules and Cells. 10 (1): 54–60. doi:10.1007/s10059-000-0054-0. PMID 10774747. S2CID 21075797.
- Page Module:Citation/CS1/styles.css has no content.Goodier MR, Londei M (July 2000). "Lipopolysaccharide stimulates the proliferation of human CD56+CD3- NK cells: a regulatory role of monocytes and IL-10". Journal of Immunology. 165 (1): 139–147. doi:10.4049/jimmunol.165.1.139. PMID 10861046.
- Page Module:Citation/CS1/styles.css has no content.Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, Rajalingam R, et al. (March 2001). "Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism". Journal of Immunology. 166 (5): 2992–3001. doi:10.4049/jimmunol.166.5.2992. PMID 11207248.
- Page Module:Citation/CS1/styles.css has no content.Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D, et al. (March 2002). "Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype". Journal of Immunology. 168 (5): 2307–2315. doi:10.4049/jimmunol.168.5.2307. PMID 11859120.
- Page Module:Citation/CS1/styles.css has no content.Chan HW, Kurago ZB, Stewart CA, Wilson MJ, Martin MP, Mace BE, et al. (January 2003). "DNA methylation maintains allele-specific KIR gene expression in human natural killer cells". The Journal of Experimental Medicine. 197 (2): 245–255. doi:10.1084/jem.20021127. PMC 2193817. PMID 12538663.
- Page Module:Citation/CS1/styles.css has no content.Becker S, Tonn T, Füssel T, Uhrberg M, Bogdanow M, Seifried E, et al. (February 2003). "Assessment of killer cell immunoglobulinlike receptor expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR expression independent of anticipated HLA class I ligands". Human Immunology. 64 (2): 183–193. doi:10.1016/S0198-8859(02)00802-9. PMID 12559621.
- Page Module:Citation/CS1/styles.css has no content.Dorothée G, Echchakir H, Le Maux Chansac B, Vergnon I, El Hage F, Moretta A, et al. (October 2003). "Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma". Oncogene. 22 (46): 7192–7198. doi:10.1038/sj.onc.1206627. PMID 14562047. S2CID 23893345.
- Page Module:Citation/CS1/styles.css has no content.Artavanis-Tsakonas K, Eleme K, McQueen KL, Cheng NW, Parham P, Davis DM, et al. (November 2003). "Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes". Journal of Immunology. 171 (10): 5396–5405. doi:10.4049/jimmunol.171.10.5396. PMID 14607943.
- Page Module:Citation/CS1/styles.css has no content.Meenagh A, Williams F, Sleator C, Halfpenny IA, Middleton D (September 2004). "Investigation of killer cell immunoglobulin-like receptor gene diversity V. KIR3DL2". Tissue Antigens. 64 (3): 226–234. doi:10.1111/j.1399-0039.2004.00272.x. PMID 15304002.
- Page Module:Citation/CS1/styles.css has no content.Yan LX, Zhu FM, Jiang K, Lv QF, He JJ (September 2006). "Investigation of killer cell immunoglobulin-like receptors gene KIR3DL2 diversity and confirmation of KIR3DL2*015 in a Chinese population". Tissue Antigens. 68 (3): 220–224. doi:10.1111/j.1399-0039.2006.00651.x. PMID 16948642.
- Page Module:Citation/CS1/styles.css has no content.Ortonne N, Bagot M, Bensussan A (2006). "[KIR3DL2: a new step for the management of patients with Sezary syndrome]". Médecine/Sciences. 22 (8–9): 691–693. doi:10.1051/medsci/20062289691. PMID 16962036.
- Page Module:Citation/CS1/styles.css has no content.Gedil MA, Steiner NK, Hurley CK (September 2007). "KIR3DL2: diversity in a hematopoietic stem cell transplant population". Tissue Antigens. 70 (3): 228–232. doi:10.1111/j.1399-0039.2007.00880.x. PMID 17661911.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.